11-Oxygenated Androgens Useful in the Setting of Discrepant Conventional Biomarkers in 21-Hydroxylase Deficiency
Open accessThe DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Abstract
Context: Serum 17-hydroxyprogesterone (17OHP) and androstenedione (A4) are the conventional biomarkers used to assess disease control in patients with 21-hydroxylase deficiency (21OHD). However, discrepancy between the two is not uncommon, limiting interpretation. Objective: To evaluate 11-oxyandrogens in discriminating good versus poor disease control in 21OHD in the setting of discrepant 17OHP and A4. Methods: Retrospective analysis of 2738 laboratory assessments obtained as part of Natural History Study of congenital adrenal hyperplasia (CAH) at the National Institutes Health Clinical Center. Patients with discrepant 17OHP and A4 and available sera were selected. A 15-steroid mass-spectrometry panel was performed in sera from patients with 21OHD and age- and sex-matched controls. Patients were categorized in “good” or “poor” control based on clinical assessment (bone age advancement, signs and symptoms of precocious puberty, menstrual irregularity, hirsutism, or hypogonadotrophic hypogonadism). Results: Discrepant 17OHP and A4 was found in 469 (17%) laboratory assessments. Of these, 403 (86%) had elevated 17OHP with A4 in reference range. Of 46 patients with available sera, 30 (65%) were in good control. Median fold elevation relative to controls was higher in patients with poor versus good control for 11-hydroxytestosterone (median [interquartile range], 2.82 [1.25-5.43] vs 0.91 [0.49- 2.07], P = .003), and 11-ketotestosterone (3.57 [2.11-7.41] vs 1.76 [1.24-4.00], P = .047). Fold elevation of 11-hydroxytestosterone between 3.48 (sensitivity 97%, specificity 47%) and 3.88 (sensitivity 100%, specificity 40%) provided the best discrimination between poor vs good control. Conclusion: 11-Oxyandrogens, especially 11-hydroxytestosterone, may be useful in the management of CAH when conventional biomarkers are inconclusive.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional challenges in the management of 21OHD derive from the uncertainties surrounding the optimal use of biomarkers to assess disease control (10, 11).”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [11]
In the citing paper
“11-oxyandrogens were found to correlate with parameters of poor 21OHD control (11, 17).”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [11]
In the citing paper
“Although 17OHP and A4 show good correlation, we previously found that 17% of laboratory evaluations done in the early morning resulted in discrepant findings between these two traditional biomarkers (11).”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [11]
In the citing paper
“A retrospective analysis of >2,700 laboratory assessments in patients with CAH showed that 17% of samples had discrepant 17-OHP and androstenedione, and that elevated 11-oxygenated androgens could be used to identify those with poor disease control when traditional biomarkers are inconclusive52.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [52]
Citations
Cites
Moving to a World Beyond “ p < 0.05”
Wasserstein, R. L., Schirm, A. L., & Lazar, N. A. (2019) · The American Statistician · doi:10.1080/00031305.2019.1583913 · Cited by 2,976
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234 · cited 2×
“The most common form is 21-hydroxylase deficiency (21OHD), with its classic form accounting for more than 95% of all cases and affecting 1 in 14 000 to 1 in 18 000 newborns [1].”
BackgroundSelf-citationMartin, K. A., Chang, R. J., Ehrmann, D. A., Ibanez, L., Lobo, R. A., Rosenfield, R. L., Shapiro, J., Montori, V. M., & Swiglo, B. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2437 · Cited by 512
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341 · cited 1×
“Patients with 21OHD need lifetime glucocorticoid and mineralocorticoid replacement at doses adequate to treat adrenal insufficiency and to avoid excess accumulation of androgens, which are produced from accumulation of the precursor products 17OHP and A4 [2].”
BackgroundSelf-citationMartin, K. A., Anderson, R. R., Chang, R. J., Ehrmann, D. A., Lobo, R. A., Murad, M. H., Pugeat, M. M., & Rosenfield, R. L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00241 · Cited by 339 · cited 1×
“For example, it may take 6 to 12 months after an intervention to see an improvement in hirsutism [36].”
BackgroundClinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313 · cited 1×
“A serum 17OHP level of 1200 ng/dL is often used as the upper limit of acceptable range [7, 8].”
BackgroundSelf-citationPW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome
O’Reilly, M. W., Kempegowda, P., Jenkinson, C., Taylor, A. E., Quanson, J. L., Storbeck, K.-H., & Arlt, W. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3285 · Cited by 267
Turcu, A. F., Nanba, A. T., Chomic, R., Upadhyay, S. K., Giordano, T. J., Shields, J. J., Merke, D. P., Rainey, W. E., & Auchus, R. J. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1181 · Cited by 231 · cited 3×
“Elevated 11-oxyandrogens correlate positively with total adrenal volume and testicular adrenal rest tumors in patients with 21OHD, [25] and these steroids show a median elevation of 3- to 4-fold relative to age- and sex-matched controls in patients with 21OHD [24].”
BackgroundSelf-citation
Research works printed but not linked: 2
- Soldin, Androstenedione.
- Keenan, 1979, Androstenedione concentration as an index of adrenal androgen suppression, J Lab Clin Med., 94, 799
Cited by
Basics of androgen synthesis and action
Naamneh Elzenaty, R., du Toit, T., & Flück, C. E. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101665 · Cited by 199
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Self-citationDisorders of Sex Development of Adrenal Origin
Finkielstain, G. P., Vieites, A., Bergadá, I., & Rey, R. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.770782 · Cited by 67
“On the other hand, 11-ketoandrostenedione and 11-ketotestosterone are produced in the kidneys from 11-hydroxyandrostenedione by 11b-hydroxysteroid dehydrogenase type 2 (63).”
BackgroundThe clinical and biochemical significance of 11-oxygenated androgens in human health and disease
Storbeck, K.-H., & O’Reilly, M. W. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad047 · Cited by 63
Sarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 35
Self-citationNovel treatments for congenital adrenal hyperplasia
Schröder, M. A. M., & der Grinten, H. L. C. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09717-w · Cited by 35
“Next to these traditional biomarkers, 11-oxygenated androgens may have potential in the management of CAH but are not yet routinely measured [4, 5].”
BackgroundLong‐term health consequences of congenital adrenal hyperplasia
Pofi, R., Ji, X., Krone, N. P., & Tomlinson, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14967 · Cited by 30
“12,13 While these biomarkers do show promise, they are not used routinely in the management of patients with CAH.”
Biomarkers in congenital adrenal hyperplasia
Bacila, I. A., Lawrence, N., Badrinath, S. G., Balagamage, C., & Krone, N. P. (2023) · Clinical Endocrinology · doi:10.1111/cen.14960 · Cited by 26
Ljubicic, M. L., Madsen, A., Juul, A., Almstrup, K., & Johannsen, T. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.652888 · Cited by 26
Auer, M. K., Paizoni, L., Neuner, M., Lottspeich, C., Schmidt, H., Bidlingmaier, M., Hawley, J. M., Keevil, B. G., & Reisch, N. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105921 · Cited by 25
“It has been suggested in a recent study that measurement of these steroids may be useful in the context of discrepancies in 17-OHP and A4 regarding treatment control [33].”
Sarafoglou, K., & Auchus, R. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae759 · Cited by 23
“In children with 21OHD, 11KT was higher in those with poor vs good disease control and was often consistent with clinical assessment of disease control when 17OHP and A4 were discordant (5).”
Self-citationTurcu, A. F., Mallappa, A., Nella, A. A., Chen, X., Zhao, L., Nanba, A. T., Byrd, J. B., Auchus, R. J., & Merke, D. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.751191 · Cited by 20
“Additional challenges in the management of 21OHD derive from the uncertainties surrounding the optimal use of biomarkers to assess disease control (10, 11).”
BackgroundResultSelf-citationReference intervals for serum 11-oxygenated androgens in children
Adriaansen, B. P. H., Oude-Alink, S., Swinkels, D. W., Schröder, M. A. M., Span, P. N., Sweep, F. C. G. J., der Grinten, H. L. C., & van Herwaarden, A. E. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae008 · Cited by 18
Congenital adrenal hyperplasia: New biomarkers and adult treatments
Dreves, B., Reznik, Y., & Tabarin, A. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.01.008 · Cited by 15
He, X., Banker, M. M., Puttabyatappa, M., Padmanabhan, V., & Auchus, R. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab793 · Cited by 12
Self-citationAnalysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry
Lawrence, N., Bacila, I. A., Dawson, J., Bryce, J., Ali, S., van den Akker, E. L. T., Bachega, T. A. S. S., Baronio, F., Birkebæk, N., Bonfig, W., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14796 · Cited by 11
“However, it has been suggested they perform better in adults than children.(22) In our extraction of data for modelling, 66% of clinic assessments had either 17OHP or D4 measured, indicating the high”
BackgroundMonitoring treatment in pediatric patients with 21-hydroxylase deficiency
Itonaga, T., & Hasegawa, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1102741 · Cited by 11
Yazawa, T., Watanabe, Y., Yokohama, Y., Imamichi, Y., Hasegawa, K., Nakajima, K.-I., Kitano, T., Ida, T., Sato, T., Islam, M. S., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1480722 · Cited by 10
LC-MS/MS the First 20 years: A Personal View
Keevil, B. G. (2021) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632211040059 · Cited by 8
“Early examples of this of this approach include the multiplexed analysis of immunosuppressant drugs12 and azole antifungal drugs.13 Multiplexed LC-MS/MS panels are now opening up the field of steroid analysis and are driving studies into the investigation of polycystic ovarian syndrome (PCOS)14 and congenital adrenal…”
BackgroundChallenges in managing disorders of sex development associated with adrenal dysfunction
Finkielstain, G. P., & Rey, R. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256393 · Cited by 6
Zeidler, R. B., Wagner, F., Ceglarek, U., Kiess, W., Kratzsch, J., Baber, R., Wirkner, K., Isermann, B., Gaudl, A., Vogel, M., et al. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1440 · Cited by 5
“In recent years, several studies comparing healthy donors and patients revealed diagnostic potential for 11-OAs in disorders with androgen excess, such as polycystic ovarian syndrome (PCOS) [12], congenital adrenal hyperplasia (CAH) [5, 13], and premature adrenarche [3, 5].”
Auer, M. K., Büyükerzurmulu, D., Lottspeich, C., Bidlingmaier, M., Rieger, E., Nowotny, H. F., Tschaidse, L., Auchus, R. J., & Reisch, N. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae112 · Cited by 3
Self-citationDubinski, I., Pozza, S. B., Bidlingmaier, M., Hawley, J. M., Keevil, B. G., Kunz, S. L., Nowotny, H. F., Reisch, N., Schiergens, K. A., Tschaidse, L., et al. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0027 · Cited by 3
Current insights into monitoring of congenital adrenal hyperplasia
Leusink, Q. M., Verploegen, E., Adriaansen, B. P. H., Chin, X., Stikkelbroeck, N. M. M. L., Span, P. N., Sweep, F. C. G. J., Dona, M., van Herwaarden, A. E., & der Grinten, H. L. C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1774145 · Cited by 2
Carmina, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-82591-1_6 · Cited by 2
Diversity of Androgens; Comparison of Their Significance and Characteristics in Vertebrate Species
Yazawa, T., Imamichi, Y., Sato, T., Ida, T., Umezawa, A., & Kitano, T. (2024) · ZOOLOGICAL SCIENCE · doi:10.2108/zs230064 · Cited by 2
“…are elevated in girls and women who suffer from excessive-androgen diseases, such as premature adrenarche (Rege et al., 2018), 21-hydroxylase deficiency (Turcu et al., 2016, 2017; Jha et al., 2021), and polycystic ovary syndrome (O’Reilly et al., 2017; Yoshida et al., 2018; Taylor et al., 2022).”
BackgroundHasegawa, Y., Itonaga, T., Ishii, T., Izawa, M., & Amano, N. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001369 · Cited by 1
Rey, R. A. (2021) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2021-0072 · Cited by 1
Rey, R. A. (2021) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2021-0074
Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry
Lawrence, N., Bacila, I. A., Dawson, J., Bryce, J., van, D. A. E., Sartori, S. B. T. A., Baronio, F., Birkebæk, N., Bonfig, W., Claahsen, H., et al. (2021) · Endocrine Abstracts · doi:10.1530/endoabs.78.p1
Honour, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818124-9.00004-8
21-Hydroxylase deficiency: Clinical and biochemical aspects
Nordenström, A., & Lajić, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00171-0
The value of 11-oxygenated androgens in the diagnosis and treatment of 21-hydroxylase deficiencyPreprint
Lan, T., Ruan, W., Chen, K., Yang, M., Chen, X., & Yao, H. J. (2025) · Research Square · doi:10.21203/rs.3.rs-6484008/v1
Teasdale, S., Joshi, K., Huynh, T., & Conwell, L. S. (2025) · Internal Medicine Journal · doi:10.1111/imj.70174
“24 Of the conventionally measured androgens, testosterone is the main effector steroid.”
Schiffer, L., Anthony, A. V., Wittemans, L. B. L., Taylor, A., Oestlund, I., Miranda, A. M. A., Melson, E., McDonnell, T., Kempegowda, P., Smith, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.27.714735
Grouthier, V. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(25)84232-x
Suzuki, E., Sawano, K., Kuroki, Y., Dateki, S., Nagasaki, K., & Fukami, M. (2026) · Molecular Syndromology · doi:10.1159/000553259
Female infertility in nonclassic congenital adrenal hyperplasia: beyond hyperandrogenism
Wang, S., Li, X., Zhang, N., Zhang, X., & Wu, X. (2026) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-026-01603-3
Kouri, C., Sommer, G., Costa, F. C., de Miranda, M. C., du Toit, T., Heldt, K., Hess, M., Hirschberg, A. L., Markosyan, R. L., Neumann, U., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag160
The evolution of new approaches to the treatment of congenital adrenal hyperplasia
Merke, D. P., & Auchus, R. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag033
Self-citationLan, T., Ruan, W., Chen, K., Yang, M., Chen, X., & Yao, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1913565
Management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: an update
Bobrowicz, M., Roszkowska, Z., Domański, J., Ginalska-Malinowska, M., Rak, B., Gastoł, P., Betlejewska, J., Gładka, A., Hubska, J., & Ambroziak, U. (2026) · Endokrynologia Polska · doi:10.5603/ep.110211
Metadata
- Authors
- Jha, S., Turcu, A. F., Sinaii, N., Brookner, B., Auchus, R. J., & Merke, D. P.
- Affiliations
- National Institutes of Health (US)
- University of Michigan (US)
- Corresponding author
- Merke, Deborah P
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2020-12-11
- Volume
- 5
- Issue
- 2
- Pages
- bvaa192-bvaa192
- ISSN
- 2472-1972 (ISSN-L)
- PMC
- PMC7796775
- OpenAlex
- W3123696312
- Cited by
- 39
- References
- 40
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 8 · 2023: 8 · 2022: 4 · 2021: 10
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- Locations
- Journal of the Endocrine Society (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (1K08DK109116)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- 21-hydroxylase deficiency, congenital adrenal hyperplasia, 11-ketotestosterone, 17-hydroxyprogesterone, androstenedione, disease control assessment, precocious puberty
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.